Recent Updates
Recently added Catalysts
CMPX Positive Sentiment Score: 70/100

Compass Therapeutics to Participate in Upcoming Investor Events

Key Takeaway: Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced its participation in several investor events in September 2023, including the Citi BioPharma Conference and H.C. Wainwright Global Investment Conference. The company aims to highlight its clinical-stage antibody-based therapeutics focused on oncology. Presentations will allow the company to engage with potential investors and partners, showcasing their pipeline and advancements in treating human diseases. Webcast links for these events have been provided for interested stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor events indicates market confidence.
  • Showcases company's commitment to advancing its clinical pipeline.
  • Opportunities for increased visibility and potential funding.

Full Press Release Details

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2023.
Details are as follows:
Citi’s 18th Annual BioPharma Conference
Location: Boston, MA
Format: 1x1 Meetings
Date: Thursday, September 7
H.C. Wainwright 25th Annual Global Investment Conference
Location: New York, NY
Format: Presentation
Date: Monday, September 11
Cantor Fitzgerald Global Healthcare Conference
Location: New York, NY
Format: Fireside Chat
Date: Wednesday, September 27
Time: 2:25-2:55 PM ET
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Anna Gifford, Communications Manager

Tags

Frequently Asked Questions

What conferences will Compass Therapeutics attend in September 2023?

Compass Therapeutics will attend Citi's BioPharma Conference and the H.C. Wainwright Global Investment Conference.

What is the date for the Canto Fitzgerald Healthcare Conference?

The Cantor Fitzgerald Global Healthcare Conference is scheduled for September 27, 2023.

Where is Compass Therapeutics headquartered?

Compass Therapeutics is headquartered in Boston, Massachusetts.

What is the main focus of Compass Therapeutics?

Compass Therapeutics focuses on developing antibody-based therapeutics for oncology.

When will presentations be available for replay?

Presentation replays will be archived for 90 days on Compass' Events page.

Last updated: Aug 30, 2023